Valuation: Cizzle Biotechnology Holdings Plc

Capitalization 63.42L 85.1L 72.41L 67.6L 1.17Cr 77Cr 1.28Cr 7.88Cr 3.06Cr 36Cr 3.19Cr 3.13Cr 132.13Cr P/E ratio 2023
-4.04x
P/E ratio 2024 -2.77x
Enterprise value 59.55L 79.91L 67.99L 63.48L 1.1Cr 72Cr 1.2Cr 7.4Cr 2.87Cr 34Cr 3Cr 2.94Cr 124.07Cr EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
56.35%
Yield 2023 *
-
Yield 2024 -
More valuation ratios * Estimated data
Dynamic Chart
Current month-3.03%
1 month-15.79%
3 months+18.52%
6 months-8.57%
Current year+3.23%
More quotes
1 week 1.5
Extreme 1.5
1.7
1 month 1.5
Extreme 1.5
2.1
Current year 1.2
Extreme 1.2
2.68
1 year 1.2
Extreme 1.2
2.68
3 years 1.2
Extreme 1.2
4.84
5 years 1.2
Extreme 1.2
13
10 years 1.2
Extreme 1.2
13
More quotes
Manager TitleAgeSince
Director of Finance/CFO 64 14/05/2021
Chief Tech/Sci/R&D Officer 60 02/01/2025
Director TitleAgeSince
Director/Board Member 43 29/01/2019
Chairman 68 21/05/2019
Director/Board Member 60 14/05/2021
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
0.00%0.00%-11.11%0.00% 84.55L
-2.53%-5.31%+0.19%+14.63% 4.7TCr
+1.37%-0.55%+11.21%+8.37% 3.8TCr
-0.57%-5.04%+71.11%+62.86% 3.57TCr
+0.54%+1.85%+11.96%+17.47% 2.76TCr
+0.96%-1.79%+65.57%+175.14% 1.58TCr
+0.81%+1.06%+66.02%+230.15% 1.51TCr
+2.19%+1.14%-12.05%-2.48% 1.42TCr
-1.61%-1.40%+64.13% - 1.34TCr
+0.65%-3.30%+106.85%+111.04% 1.27TCr
Average +0.21%-1.46%+37.39%+68.57% 2.19TCr
Weighted average by Cap. -0.11%-1.90%+33.62%+55.03%
See all sector performances

Financials

2023 2024
Net sales - -
Net income -17.17L -23.04L -19.6L -18.3L -31.75L -21Cr -34.56L -2.13Cr -82.85L -9.82Cr -86.46L -84.63L -36Cr -21.66L -29.06L -24.73L -23.09L -40.05L -26Cr -43.6L -2.69Cr -1.05Cr -12Cr -1.09Cr -1.07Cr -45Cr
Net Debt -15.57L -20.89L -17.78L -16.6L -28.79L -19Cr -31.34L -1.93Cr -75.13L -8.9Cr -78.4L -76.74L -32Cr -4L -5L -4L -4L -7L -4.68Cr -8L -48.06L -18.67L -2.21Cr -19.49L -19.07L -8.06Cr
More financial data * Estimated data
Logo Cizzle Biotechnology Holdings Plc
Cizzle Biotechnology Holdings Plc is a United Kingdom-based diagnostics development company. The Company is engaged in the development of a blood test for the early detection of lung cancer. Its prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a cell nuclear protein involved in deoxyribonucleic acid (DNA) replication, and the targeted CIZ1B variant is correlated with early-stage lung cancer. Its prototype confirmative test has been developed to address the false positive rates of computed tomography (CT) scanning. The test is intended to address a clear unmet clinical need, which is early detection of lung cancer, when curative surgical resection is possible.
Employees
4
More about the company
Date Price Change Volume
11/25/11 1.600 p 0.00% 1,79,485
10/25/10 1.600 p 0.00% 3,07,630
09/25/09 1.600 p 0.00% 2,37,187
08/25/08 1.600 p 0.00% 2,38,227
05/25/05 1.600 p 0.00% 6,513

Delayed Quote London S.E., December 11, 2025 at 10:05 pm IST

More quotes